Bufexamac

	WikiDoc Resources for Bufexamac
Articles
Most recent articles on Bufexamac Most cited articles on Bufexamac Review articles on Bufexamac Articles on Bufexamac in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bufexamac Images of Bufexamac Photos of Bufexamac Podcasts & MP3s on Bufexamac Videos on Bufexamac
Evidence Based Medicine
Cochrane Collaboration on Bufexamac Bandolier on Bufexamac TRIP on Bufexamac
Clinical Trials
Ongoing Trials on Bufexamac at Clinical Trials.gov Trial results on Bufexamac Clinical Trials on Bufexamac at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bufexamac NICE Guidance on Bufexamac NHS PRODIGY Guidance FDA on Bufexamac CDC on Bufexamac
Books
Books on Bufexamac
News
Bufexamac in the news Be alerted to news on Bufexamac News trends on Bufexamac
Commentary
Blogs on Bufexamac
Definitions
Definitions of Bufexamac
Patient Resources / Community
Patient resources on Bufexamac Discussion groups on Bufexamac Patient Handouts on Bufexamac Directions to Hospitals Treating Bufexamac Risk calculators and risk factors for Bufexamac
Healthcare Provider Resources
Symptoms of Bufexamac Causes & Risk Factors for Bufexamac Diagnostic studies for Bufexamac Treatment of Bufexamac
Continuing Medical Education (CME)
CME Programs on Bufexamac
International
Bufexamac en Espanol Bufexamac en Francais
Business
Bufexamac in the Marketplace Patents on Bufexamac
Experimental / Informatics
List of terms related to Bufexamac

Bufexamac
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Topical, rectal
ATC code	M01AB17 (WHO) M02AA09 (WHO);
Legal status
Legal status	In general: Over-the-counter (OTC);
Pharmacokinetic data
Excretion	Renal
Identifiers
	IUPAC name 2-(4-butoxyphenyl)-N-hydroxyacetamide;
CAS Number	2438-72-4;
PubChem CID	2466;
ChemSpider	2372;
UNII	4T3C38J78L;
ChEMBL	ChEMBL94394;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C12H17NO3
Molar mass	223.268 g/mol
3D model (JSmol)	Interactive image;
	SMILES ONC(=O)Cc1ccc(OCCCC)cc1;
	InChI InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14); Key:MXJWRABVEGLYDG-UHFFFAOYSA-N;

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe because of allergic reactions.

Indications

Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns,^{[citation needed]} and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.^[1]

Pharmacology

Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it a non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.^[2] Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10),^[3] which may contribute to its clinical efficacy.^{[citation needed]}

Side effects

Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.^[4] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.^[5]

References

↑ Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German). 2 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
↑ Gloor, Max; Thoma, Karl; Fluhr, Joachim (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349. ISBN 3-540-67174-9.
↑ Bantscheff, Marcus; Hopf, Carsten; Savitski, Mikhail M; Dittmann, Antje; Grandi, Paola; Michon, Anne-Marie; Schlegl, Judith; Abraham, Yann; Becher, Isabelle; Bergamini, Giovanna; Boesche, Markus; Delling, Manja; Dümpelfeld, Birgit; Eberhard, Dirk; Huthmacher, Carola; Mathieson, Toby; Poeckel, Daniel; Reader, Valérie; Strunk, Katja; Sweetman, Gavain; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel G; Drewes, Gerard (2011). "Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes". Nature Biotechnology. 29 (3): 255–65. doi:10.1038/nbt.1759. PMID 21258344.
↑ "Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft". Deutsches Ärzteblatt (in German) (47). 2000.
↑ "European Medicines Agency recommends revocation of marketing authorisations for bufexamac" (PDF). European Medicines Agency. 2010-04-22.

Template:Topical products for joint and muscular pain

[Arzneistoff-Profile-1] Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German). 2 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.

[2] Gloor, Max; Thoma, Karl; Fluhr, Joachim (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349. ISBN 3-540-67174-9.

[3] Bantscheff, Marcus; Hopf, Carsten; Savitski, Mikhail M; Dittmann, Antje; Grandi, Paola; Michon, Anne-Marie; Schlegl, Judith; Abraham, Yann; Becher, Isabelle; Bergamini, Giovanna; Boesche, Markus; Delling, Manja; Dümpelfeld, Birgit; Eberhard, Dirk; Huthmacher, Carola; Mathieson, Toby; Poeckel, Daniel; Reader, Valérie; Strunk, Katja; Sweetman, Gavain; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel G; Drewes, Gerard (2011). "Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes". Nature Biotechnology. 29 (3): 255–65. doi:10.1038/nbt.1759. PMID 21258344.

[4] "Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft". Deutsches Ärzteblatt (in German) (47). 2000.

[5] "European Medicines Agency recommends revocation of marketing authorisations for bufexamac" (PDF). European Medicines Agency. 2010-04-22.

[1]

[2]

[3]

[4]

[5]

v t e Nonsteroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
Pyrazolones / Pyrazolidines	Aminophenazone Ampyrone Azapropazone Clofezone Difenamizole Famprofazone Feprazone Kebuzone Metamizole Mofebutazone Morazone Nifenazone Oxyphenbutazone Phenazone Phenylbutazone Propyphenazone Sulfinpyrazone Suxibuzone^‡
Salicylates	Aspirin (acetylsalicylic acid)^# Aloxiprin Benorylate Carbasalate calcium Diflunisal Dipyrocetyl Ethenzamide Guacetisal Magnesium salicylate Methyl salicylate Salsalate Salicin Salicylamide Salicylic acid (salicylate) Sodium salicylate
Acetic acid derivatives and related substances	Aceclofenac Acemetacin Alclofenac Amfenac Bendazac Bromfenac Bumadizone Bufexamac Diclofenac Difenpiramide Etodolac Felbinac Fenclozic acid Fentiazac Indometacin Indometacin farnesil Isoxepac Ketorolac Lonazolac Oxametacin Prodolic acid Proglumetacin Sulindac Tiopinac Tolmetin Zomepirac^†
Oxicams	Ampiroxicam Droxicam Isoxicam Lornoxicam Meloxicam Piroxicam Tenoxicam
Propionic acid derivatives (profens)	Alminoprofen Benoxaprofen^† Carprofen^‡ Dexibuprofen Dexketoprofen Fenbufen Fenoprofen Flunoxaprofen Flurbiprofen Ibuprofen^# Ibuproxam Indoprofen^† Ketoprofen Loxoprofen Miroprofen Naproxen Oxaprozin Pirprofen Suprofen Tarenflurbil Tepoxalin^‡ Tiaprofenic acid Vedaprofen^‡ Zaltoprofen COX-inhibiting nitric oxide donator: Naproxcinod
N-Arylanthranilic acids (fenamates)	Azapropazone Clonixin Etofenamate Flufenamic acid Flunixin Meclofenamic acid Mefenamic acid Morniflumate Niflumic acid Tolfenamic acid Flutiazin
Coxibs	Apricoxib Celecoxib Cimicoxib^‡ Deracoxib^‡ Etoricoxib Firocoxib^‡ Lumiracoxib^† Mavacoxib^‡ Parecoxib Robenacoxib^‡ Rofecoxib^† Valdecoxib^†
Other	Aminopropionitrile Benzydamine Chondroitin sulfate Diacerein Fluproquazone Glucosamine Glycosaminoglycan Hyperforin Nabumetone Nimesulide Oxaceprol Proquazone Superoxide dismutase/Orgotein Tenidap
Items listed in bold indicate initially developed compounds of specific groups. ^#WHO-EM ^†Withdrawn drugs. ^‡Veterinary use medications.

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Topical, rectal
ATC code	M01AB17 (WHO) M02AA09 (WHO)
Legal status
Legal status	In general: Over-the-counter (OTC)
Pharmacokinetic data
Excretion	Renal
Identifiers
IUPAC name 2-(4-butoxyphenyl)-N-hydroxyacetamide
CAS Number	2438-72-4
PubChem CID	2466
ChemSpider	2372
UNII	4T3C38J78L
ChEMBL	ChEMBL94394
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₂H₁₇NO₃
Molar mass	223.268 g/mol
3D model (JSmol)	Interactive image
SMILES ONC(=O)Cc1ccc(OCCCC)cc1
InChI InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14) Key:MXJWRABVEGLYDG-UHFFFAOYSA-N